ABSTRACT
INTRODUCTION
Fetal growth restriction (FGR), a condition in which a fetus is unable to achieve its genetically determined potential size, affects about 8% of pregnancies and is associated with increased perinatal mortality and morbidity 1 . Several studies have investigated cardiovascular adaptation in pregnancies complicated by FGR, finding that, compared with normal pregnancies, affected pregnancies typically demonstrate reduced expansion of the maternal intravascular space, a lack of increase in stroke volume (SV) and cardiac output (CO) in the very early phase of pregnancy and decreased preload 2, 3 .
Nitric oxide (NO) is an autocrine and paracrine signalling molecule that is synthesized from L-arginine by a family of calcium-calmodulin-dependent enzymes called NO synthases. It is released by endothelial cells and physiologically it has a vasodilatory effect, increasing blood flow. Moreover, it causes decreased responsiveness to vasopressors and inhibition of platelet function 4 . NO is involved in regulating placental vascular tone and development 5 and apparently plays an important role in normal placental development; it is produced in the uteroplacental tissues and is associated with a reduction in vascular resistance of the fetoplacental and uterine circulations 6 . These important features of NO in improving uteroplacental perfusion could provide us with a therapeutic strategy for management of pregnancies complicated by FGR; utilizing NO donors in association with plasma volume expansion by co-administration of oral fluids, the vasodilatory function of NO may improve pregnancy outcome in these cases by acting on the maternal systemic vascular resistance (SVR).
The aim of this study was to evaluate the maternal cardiovascular effects of treatment with a NO donor and plasma volume expansion in pregnancies complicated by FGR.
the Fetal Medicine Unit at St George's Hospital, University of London. Over a continuous 6-month period, we considered for inclusion 30 women with singleton pregnancy complicated by FGR, defined as an estimated fetal weight (EFW) < 10 th percentile and abnormal umbilical artery (UA) Doppler. Exclusion criteria were: chromosomal abnormality, preterm rupture of membranes, intrauterine infection, undetermined gestational age, history of maternal heart disease, tobacco use and pre-existing chronic medical problems. Four patients were lost to follow-up and therefore excluded.
The remaining 26 patients were enrolled, forming the 'treated' group. These women were treated until delivery with a NO donor (transdermal glycerine trinitrate (GTN) patches, utilized for 12 h a day to prevent tolerance from building up, at a dosage of 5 mg/24 h) along with oral fluid (water) intake (2.5 L per day). For each case in this group, we included, from a historical group of untreated FGR patients who had been assessed at diagnosis and 2 weeks later, one control, matched for maternal age (± 1 year), body mass index (BMI) (± 1 kg/m 2 ), gestational age (± 1 week) and severity of disease (i.e. with similar EFW and fetal Doppler velocimetry) (untreated group). All women underwent hemodynamic assessment and fetal ultrasound examination at diagnosis (immediately prior to initiation of treatment in the group undergoing treatment) and all underwent hemodynamic assessment again 2 weeks later.
Approval of the local ethics committee was obtained based on the submitted protocol, and informed consent was obtained from patients and controls prior to enrolment.
Fetal ultrasound examinations were performed at the time of diagnosis by a sonographer, using a Voluson E6 ultrasound machine (GE Healthcare Ultrasound, Milwaukee, WI, USA), equipped with a 3.5-MHz sector-array transducer. Fetal biometry and EFW were assessed according to local reference values 7 . Doppler measurements were obtained from the UA, fetal middle cerebral artery (MCA) and uterine artery.
Maternal hemodynamic assessment, at the time of diagnosis and 2 weeks later, was carried out by one of two trained operators using an UltraSonic Cardiac Output Monitor (USCOM ® , USCOM Ltd., Coffs Harbour, Australia). USCOM ® , non-invasive Doppler ultrasonic technology for determination of hemodynamic variables, has been validated against invasive gold standards [8] [9] [10] . Briefly, a non-imaging, continuous-wave Doppler transducer is placed at the suprasternal notch to measure transaortic or transpulmonary blood flow. The acoustic beam is directed in line with the valvular flow and a time-velocity spectral display is generated, showing variations in blood flow velocity over time.
Once an optimal flow profile is obtained (with maximum amplitude, triangular shape and well-defined edges, with the valve click occurring as the valve opens and closes between systole and diastole), the trace is frozen on the screen and the flow profiles are traced automatically, allowing calculation of the maternal hemodynamic variables SV, CO and SVR. SV is calculated as the product of the velocity-time integral and the cross-sectional area (CSA) of the particular valve. CSA of the aortic valve is determined from the proprietary height-indexed regression equations. CO is calculated automatically as the product of the heart rate and SV. SVR is calculated following the input of systolic (SBP) and diastolic (DBP) blood pressure or mean arterial pressure (MAP) 11 .
Statistical analysis
Analysis was performed using the SPSS (IBM Corp., Armonk, NY, USA) statistical package. Values are expressed as mean ± SD. Clinical data from the two groups were compared by means of independent-samples Student's t-test, with P < 0.05 indicating a statistically significant difference. Table 1 compares the demographic and pregnancy characteristics at diagnosis and the outcome for the group with FGR pregnancy treated with NO donor vs the untreated group. The two study populations were similar at the time of diagnosis in terms of parity, maternal age, height, weight and BMI. They also had similar EFW at diagnosis of FGR, fetal Doppler findings (UA pulsatility index (PI) and MCA-PI) and gestational age at diagnosis and at delivery. Compared with the untreated controls, the treated group had significantly higher EFW centile at diagnosis (9.20 ± 1.22 vs 6.50 ± 1.74, P < 0.0001), uterine artery PI (1.23 ± 0.20 vs 0.90 ± 0.16, P < 0.05), birth weight (2538.88 ± 490.00 vs 2303.00 ± 200.20 g, P < 0.05) and birth-weight centile (11 ± 0.5 vs 3.66 ± 1.5, P < 0.05).
RESULTS
Comparison of the weight centiles longitudinally in each group showed that both groups differed significantly in their birth-weight centile compared with their EFW centile at diagnosis. However, in the group which received treatment with NO and plasma volume expansion there was a statistically significant increase (P < 0.01), while in the untreated group there was a significant reduction (P < 0.01), in weight centile longitudinally (Table 1) . Table 2 presents the maternal hemodynamic characteristics, comparing the two groups at the time of diagnosis and analyzing each group longitudinally, from the time of diagnosis (and onset of therapy in the treated group) to 2 weeks later. There was no statistically significant difference between the two groups in any cardiovascular parameter at diagnosis. After 2 weeks of treatment, women in this group had significantly higher values of SV, SV index, CO and cardiac index (CI) compared with at diagnosis (P < 0.05) (Table 2, Figure 1 ). Moreover, this group's SVR values were significantly lower after 2 weeks of therapy (P < 0.05). In contrast, in the untreated controls, while there was a slight decrease in SVR values, this was not statistically significant, and there was no significant difference in any other parameter 2 weeks after diagnosis compared with values at diagnosis. 
Data are given as n (%) or mean ± SD. *Group which underwent treatment showed statistically significant increase in weight centile longitudinally (P < 0.01). †Untreated group showed statistically significant reduction in weight centile longitudinally (P < 0.01). BMI, body mass index; EFW, estimated fetal weight; PI, pulsatility index. 
DISCUSSION
The normal maternal cardiovascular adaptation to pregnancy includes a number of hemodynamic changes such as an increase in CO and SV, associated with a reduction in SVR and systemic arterial pressure values 2,3 . These changes take place from the earliest weeks of pregnancy, reach their peak during the second trimester and then remain relatively constant until delivery. In contrast, pregnancies complicated by FGR fail to achieve these physiological cardiovascular changes and are characterized by a general hypovolemic condition similar to a non-pregnant hemodynamic state (high resistance, low volume, hypodynamic state) 12 . In our prospective cohort study we investigated the therapeutic effect of administering a NO donor, with co-administration of oral fluids, to women with pregnancy complicated by FGR: in particular, the effect on maternal cardiovascular parameters. We hypothesized that the proposed combined therapy would change the hemodynamic features typical of FGR pregnancy 12 that seem to contribute to the pathogenesis of this obstetric complication. We achieved this by comparing these parameters in two groups of patients affected by FGR and treated differently: one group was enrolled at diagnosis of FGR and commenced treatment with a NO donor and co-administration of oral fluids, being evaluated after 2 weeks of therapy; the second group of untreated, matched patients was identified in the hospital database, and we obtained their records from assessments at diagnosis and 2 weeks later. At diagnosis, the group treated with NO had higher uterine artery Doppler PI values compared with the untreated group, suggesting that these cases might have presented with worse impairment of the placentation process. In the group treated with NO donor and oral fluids, we found, after 2 weeks' therapy, an overall improvement in the cardiac function indices CO, SV and SVR. In contrast, the cardiovascular assessments in the untreated group, at diagnosis and 2 weeks later, reflect a stable condition, with SVR values failing to drop following diagnosis.
Another important aspect of NO donor treatment is the increase in heart rate. Typically, pregnancies complicated by FGR are characterized by low heart rate compared with normal pregnancy 13 . In our study group there was a slight but non-significant increase in heart rate after 2 weeks in both groups.
The use of a historical group of untreated FGR patients as controls demonstrates that the effect of elevated SVR is a real finding. The use of this group also confirms that the effect of NO is to cause a significant reduction in SVR.
Although not our primary aim, our focus being the cardiovascular effect of NO donor therapy, we noted an improvement in fetal growth following this therapy. While the EFW for the treated group was already higher than that of the untreated group at diagnosis (9  th and  6 th percentile, respectively), and analysis of birth-weight centile showed this relationship to remain after treatment (11 th and 4 th percentile, respectively), the weight centile in fact increased significantly between diagnosis and delivery in the treated group, while it decreased in the untreated group (Table 1) , suggesting the possibility that NO therapy may contribute to improved fetal growth.
Several studies have shown that abnormalities of adaptive mechanisms in the placental vascular bed are related to several disorders of pregnancy, particularly pregnancy-induced hypertension and FGR. The use of transdermal GTN patches has been investigated extensively for both prevention and management of pre-eclampsia and related disorders 14 and has been shown effective in improving uterine and umbilical blood flow. Moreover, GTN protects syncytiotrophoblasts from apoptosis, lipid peroxidation and superoxide formation following hypoxia-reperfusion insult 15 . A prospective case-control study conducted by Melchiorre et al. 16 demonstrated that FGR pregnancies are characterized by a lower CI and higher SVR index than expected for gestational age. As regards therapy with NO donors, several studies have demonstrated their effectiveness in improving the outcome of FGR pregnancies 17, 18 . Some have demonstrated reappearance of end-diastolic flow in the UA associated with an improvement in fetal outcome during NO donor treatment 17, 18 . Our results suggest a beneficial effect of NO donor administration and fluid management in FGR pregnancy. Of particular interest is the double and synergistic action of our therapy on both afterload and preload. Oral fluid management induced an increase in preload, which is typically reduced in pregnancies complicated by FGR. At the same time, NO donor administration acted on SVR, leading to a reduction in afterload. We can speculate that CO and SVR may represent a good method with which to evaluate the efficacy of our combined therapy, confirming that this therapy improves maternal cardiovascular function, which could potentially have a positive effect on fetal growth. Our results suggest that the maternal 'cardiac pump' might play a central and decisive role in the evolution of pregnancy; the study of maternal cardiovascular function could therefore be useful in understanding the maternal response to impaired placentation and, consequently, in improving our prognostic ability.
Most studies investigate maternal hemodynamic changes and effectiveness of therapy using transthoracic echocardiography, a methodology for CO estimation in pregnancy that is widely accepted and generally considered safe due to its non-invasive nature. However, this method requires both costly equipment and clinical expertise, thereby limiting its availability. We used the USCOM ® system, a non-invasive method that is simple to use, with measurements obtained in minutes, and minimal training required to achieve operative proficiency. The accuracy of the system when compared with other methods and in various clinical applications has been proven in a number of studies. A comparison of measurements obtained by USCOM and those obtained by flow probes in a computer-controlled flow simulator demonstrated a variation of less than 5%. Dhanani et al. 19 evaluated the intra-and interobserver reliability of the USCOM method. They found a mean difference ± SD for repeat CI measurements in healthy anesthetized children by each of two observers to be 0.11 ± 0.47 and 0.05 ± 0.65 L/min/m 2 . The intraobserver reliability for repeat measurements by each observer, determined by Lin's concordance correlation coefficient, was 0.92 and 0.85, respectively, while the mean difference in CI measurement was 0. The small sample size and the observational nature of the current study are potential limitations. However, despite the small sample size, it was adequate to demonstrate the potential effectiveness of this therapy.
In conclusion, our results suggest that the combined therapeutic approach of NO donor administration and plasma volume expansion in FGR improves significantly maternal hemodynamic indices. Although our results need to be confirmed in a randomized controlled trial, with an adequate study population, they could potentially open up new perspectives in the treatment of FGR, with focus placed on SVR and CO both for evaluation of affected pregnancies and as potential targets for therapy.
